Rifampin

Introduction Overview

Generic Name

rifampin

Brand Name

Rifadin, Rifadin IV, Rimactane

Dosage Form

intravenous powder for injection (600 mg), oral capsule (150 mg; 300 mg)

Drug Class

Rifamycin derivatives

Pharmacokinetics

Absorption:
Rifampin is administered orally or intravenously. Oral absorption is rapid and generally complete, with peak plasma concentrations typically attained within 2 to 4 hours following administration on an empty stomach, as food delays absorption reducing bioavailability. The oral bioavailability is approximately 70%, but may be variable depending on gastrointestinal conditions and concurrent medications. Intravenous administration bypasses absorption variability, offering rapid systemic availability. Clinical guidelines recommend taking rifampin on an empty stomach to maximize absorption, as food and antacids may significantly reduce plasma concentrations.

Distribution:
Rifampin is widely distributed in the body tissues and fluids, including cerebrospinal fluid (CSF), lungs, bile, pericardial fluid, and pleural fluid, making it effective against various bacterial infections, including tuberculosis and meningitis prophylaxis. It is highly protein bound (~80%), primarily to albumin. The drug crosses the placental barrier and is excreted into breast milk. It has a large volume of distribution (~0.9–1.2 L/kg). Rifampin's ability to penetrate macrophages and other cells allows it to act on intracellular pathogens. Distribution is influenced by the physiological state of the patient, such as inflammation, which can increase penetration into the CSF.

Metabolism:
Rifampin undergoes extensive hepatic metabolism, predominantly via deacetylation to an active metabolite. The biotransformation involves cytochrome P450 enzymes, notably CYP3A4 induction, which not only metabolizes rifampin itself but also accelerates the metabolism of various concomitantly administered drugs. The metabolic process can be affected by hepatic function status, and rifampin is known for potent enzyme induction leading to autoinduction—where continued therapy increases its own metabolism, resulting in decreased plasma concentrations over the first few weeks of administration.

Elimination:
The primary route of excretion is biliary via the feces, with a smaller proportion eliminated by renal excretion. Approximately 30% of the dose is excreted unchanged in the bile. The elimination half-life is dose-dependent and ranges from 2 to 5 hours initially; however, due to autoinduction of metabolism, the half-life may decrease to approximately 3 hours with continued dosing. Impaired hepatic function can prolong elimination. Rifampin does not accumulate significantly with repeated dosing. Given its major hepatic metabolism, liver impairment warrants careful monitoring and possible dose adjustments.

Dosage Forms

Available Dosage Forms:
- Intravenous powder for injection: 600 mg per vial
- Oral capsules: 150 mg and 300 mg strengths

Dosages for Adults and Adolescents:
- Tuberculosis treatment: Typically, 10 mg/kg (up to 600 mg) once daily orally or intravenously. The dosage in combination with other antitubercular agents is usually maintained for 6 months or longer based on treatment guidelines.
- Meningococcal carrier eradication: 600 mg orally once daily for 4 days; used to reduce bacterial colonization in the nasopharynx.

Specific Patient Populations:
- Pediatrics: Dosage is adjusted by weight; standard dosing is 10-20 mg/kg daily, not to exceed adult maximum doses. Careful monitoring of efficacy and side effects is essential.
- Hepatic impairment: Dose adjustment may be necessary due to reduced metabolism and clearance. Close liver function monitoring is advised.
- Pregnancy: Use only if clearly needed due to potential risk of bleeding near delivery.
- Renal impairment: No significant dose adjustment usually needed; however, monitor for toxicity.

Clinical Guidelines:
Rifampin is recommended to be administered on an empty stomach—1 hour before or 2 hours after meals—to ensure optimum absorption. Intravenous administration requires dilution prior to infusion and should be given under healthcare supervision with monitoring for infusion site reactions.

Mechanism Of Action

Rifampin acts by inhibiting bacterial DNA-dependent RNA polymerase, a critical enzyme involved in the transcription process of bacterial RNA synthesis. By binding selectively to the β-subunit of this enzyme, rifampin prevents the initiation of RNA chain formation, thus inhibiting RNA synthesis and ultimately bacterial protein synthesis. This action is bactericidal for many susceptible bacteria, including Mycobacterium tuberculosis.

At a cellular level, rifampin exhibits a high affinity for the RNA polymerase present in susceptible microorganisms but has a lower affinity for mammalian enzymes, accounting for its selective toxicity. The inhibition of RNA polymerase leads to suppression of bacterial multiplication and the elimination of both extracellular and intracellular bacterial populations.

Biochemically, rifampin's lipophilic nature facilitates penetrance into phagocytic cells and tissues, enabling it to act on intracellular pathogens where bacteria might evade other antibiotics. This property is crucial in treating persistent infections such as tuberculosis.

Clinically, rifampin’s mechanism underlies its efficacy in combination therapy regimens for tuberculosis and prophylaxis of certain bacterial infections like Neisseria meningitidis carriage. Rifampin is also a potent inducer of liver enzymes (particularly cytochrome P450 isoforms), resulting in numerous drug interactions by accelerating the metabolism of coadministered drugs.

Comparatively, rifampin’s mechanism contrasts with other antibacterial agents that inhibit cell wall synthesis or interfere with protein synthesis at the ribosomal level. The unique target on bacterial RNA polymerase provides a valuable tool in multidrug regimens to prevent resistance development.

Numerous clinical studies have validated rifampin’s effectiveness as part of first-line therapy for tuberculosis and other infections, emphasizing its role in reducing bacterial load and preventing disease transmission.

Pharmacological Actions

Bactericidal activity against Mycobacterium tuberculosis and other susceptible bacteria
Inhibition of bacterial DNA-dependent RNA polymerase enzyme
Rapid tissue and intracellular penetration facilitating action against intracellular pathogens
Induction of cytochrome P450 enzymes leading to enhanced metabolism of many coadministered drugs
Reduction of bacterial colonization of the nasopharynx in meningococcal carriers
Activity against atypical mycobacteria and certain gram-positive and gram-negative bacteria
Support of combination therapy regimens to prevent emergence of drug resistance
Modulation of immune response indirectly by bacterial clearance

Therapeutic Or Clinical Uses

Treatment of active tuberculosis infection as part of multidrug regimen
Prevention and treatment of meningococcal disease carrier state
Prophylaxis of Haemophilus influenzae type b infection in exposed individuals
Adjunctive treatment in infections caused by susceptible strains of Staphylococcus aureus
Eradication of methicillin-resistant Staphylococcus aureus (MRSA) in combination therapy
Treatment of Legionella pneumonia as part of combination therapy
Treatment of leprosy in combination regimens
Management of other mycobacterial infections such as Mycobacterium avium complex (MAC)
Use in prophylaxis for certain bacterial infections in immunocompromised patients
Reduction of bacterial colonization to prevent transmission in outbreak settings
Combined therapy in endocarditis caused by susceptible organisms
Part of treatment protocols for Bartonellosis and other rare bacterial infections

Side Or Adverse Effects

Allergic reactions including rash, urticaria, and anaphylaxis
Hepatotoxicity manifesting as elevated liver enzymes, jaundice, and hepatocellular injury
Gastrointestinal disturbances such as nausea, vomiting, diarrhea, heartburn, and anorexia
Red-orange discoloration of bodily fluids including urine, sweat, saliva, tears, and teeth staining
Flu-like symptoms including fever, chills, body aches, and headache
Hematological abnormalities including thrombocytopenia, leukopenia, and anemia
Neurological effects such as dizziness, headache, confusion, numbness, and muscle weakness
Peripheral neuropathy especially in patients with predisposing conditions
Renal impairment or acute kidney injury in predisposed individuals
Hypersensitivity reactions including severe skin reactions like Stevens-Johnson syndrome
Potential for drug-induced fever and inflammatory reactions
Disruption of hormonal contraceptive effectiveness leading to unintended pregnancy
Rare cases of immune-mediated thrombocytopenia or hemolytic anemia
Fatigue and somnolence reported during therapy
Balance and coordination issues possibly related to central nervous system effects

Precautions

Use with caution in patients with pre-existing liver disease or elevated hepatic enzymes
Monitor liver function tests regularly during therapy to detect hepatotoxicity early
Evaluate for signs of bleeding disorders and hematologic abnormalities before and during therapy
Avoid concomitant use with drugs that have significant interactions and hepatotoxic potential
Inform patients regarding red-orange discoloration of body fluids to prevent alarm
Adherence to full prescribed course is critical to prevent resistance and treatment failure
Use alternative or additional birth control methods during rifampin treatment due to decreased efficacy of hormonal contraceptives
Avoid alcohol consumption to reduce risk of liver damage
Assess history of porphyria as rifampin may exacerbate symptoms
Careful use in patients with diabetes due to potential effects on blood glucose control
Cautious use in pregnant women especially near term due to bleeding risk in mother and newborn
Regular monitoring for signs of hypersensitivity or severe skin reactions is essential
Rifampin may interfere with some laboratory tests; inform laboratory personnel of rifampin usage
Discontinue or adjust therapy if severe adverse reactions or drug-induced hepatitis occur
Use with caution in patients with renal impairment; monitor renal function as appropriate

Warnings

Rifampin may cause severe hepatotoxicity including fatal liver failure
Potential for serious hypersensitivity reactions including anaphylaxis and severe skin conditions
Risk of false positive or false negative results in urine drug screening tests
Concurrent use with certain protease inhibitors and other antiretroviral drugs is contraindicated or requires dose adjustment
Do not stop rifampin abruptly without medical supervision to avoid resistance and kidney damage
Pregnant women should only use rifampin if the potential benefit justifies the risk due to bleeding risk near delivery
Rifampin induces cytochrome P450 enzymes leading to significant drug interactions that may cause therapeutic failure or toxicity
Use caution with drugs metabolized by CYP3A4 as rifampin may reduce their effectiveness
Avoid use in patients with known hypersensitivity to rifampin or related rifamycin antibiotics
Discoloration of soft contact lenses may occur and can be permanent; patients advised to avoid lens use during therapy
Educate patients about allergic and severe adverse reaction symptoms requiring immediate medical attention
Monitor for signs of flu-like syndrome that may signal systemic reaction
Use caution in patients with bleeding disorders or on anticoagulant therapy due to increased bleeding risk
Administration IV requires experienced healthcare providers to reduce infusion-related reactions
Potential risk of drug-induced lupus-like syndrome or other autoimmune reactions reported

Contraindication

Known hypersensitivity or allergy to rifampin or other rifamycin derivatives such as rifabutin, rifapentine, or rifaximin
Severe liver impairment or acute liver disease
Concomitant use with certain antiretroviral protease inhibitors like atazanavir, darunavir, fosamprenavir, ritonavir, saquinavir, and tipranavir without dose adjustment or close monitoring
Patients with a history of rifampin-induced thrombocytopenia or hemolytic anemia
Use during pregnancy near term unless clearly indicated and benefits outweigh risks
Known porphyria or other enzymatic disorders exacerbated by rifampin
Patients with active hypersensitivity reactions to rifampin
Concurrent use with certain drugs that are major substrates of CYP enzymes without possibility of monitoring and dose adjustments
Patients currently breastfeeding due to potential drug transmission and lack of safety data
Severe renal impairment with inability to monitor drug levels closely

Drug Interactions

Rifampin is a potent inducer of cytochrome P450 enzymes, notably CYP3A4, leading to decreased plasma concentration and efficacy of many coadministered drugs
Decreases effectiveness of hormonal contraceptives including pills, patches, implants, vaginal rings, and injections
Reduces the serum concentration of protease inhibitors such as atazanavir, darunavir, fosamprenavir, ritonavir, saquinavir, and tipranavir, potentially leading to therapeutic failure
Interacts with warfarin and other anticoagulants, necessitating close monitoring of coagulation parameters
Reduces efficacy of immunosuppressants like cyclosporine and tacrolimus
May decrease levels of certain antiepileptic drugs such as phenytoin and valproate
Interaction with certain antifungals like ketoconazole and itraconazole leading to reduced antifungal effect
Concomitant administration with oral hypoglycemic agents may reduce their effectiveness
Rifampin reduces blood levels of some statins such as simvastatin and atorvastatin
Interferes with digoxin metabolism reducing its plasma concentration
May alter levels of corticosteroids and oral contraceptives leading to decreased therapeutic effects
When given with benzodiazepines like midazolam, rifampin decreases their plasma levels and sedation effects
Potential interaction with antivirals such as efavirenz and nevirapine affecting antiretroviral therapy
Use with caution alongside acetaminophen, NSAIDs, and other hepatotoxic drugs to prevent additive liver toxicity
Rifampin may cause false-negative urine drug screens leading to misinterpretation of results

Preparations Of The Drug

Intravenous powder for injection: available in 600 mg vials, requiring reconstitution before administration
Oral capsules: 150 mg strength suitable for pediatric and dose-titration needs
Oral capsules: 300 mg strength generally used for adult dosing convenience
Commercial formulations designed to be stable at room temperature away from moisture and heat
Instructions to take oral dosage forms on an empty stomach with a full glass of water to optimize absorption
Parenteral formulation intended for hospital or clinical setting under supervision, with monitoring for infusion site reactions
Packaging includes detailed patient information leaflets highlighting side effects, drug interactions, and administration guidelines
Capsules should be stored in tightly closed containers to prevent degradation
Availability in generic and brand-name products to support accessibility and affordability
Compatibility considerations for intravenous infusion solutions with proper diluents
Supplemental prescribing information available from professional monographs for dose adjustments in special populations
Preparations standardized for dosing accuracy in tuberculosis programs worldwide
Guidelines recommend routine blood monitoring during therapy to detect adverse effects early
Manufactured under strict regulatory standards ensuring quality, efficacy, and safety
Patient counseling materials provided to emphasize adherence and avoidance of drug interactions